National working group meeting on ALK diagnostics in lung cancer
Cooper, Wendy, Fox, Stephen, O'Toole, Sandra, Morey, Adrienne, Frances, Glenn, Pavlakis, Nick, O'Byrne, Kenneth, Dettrick, Andrew, Leong, Trishe, Rathi, Vivek, Spagnolo, Dominic, Hemmings, Chris, Singh, Mahendra, Moffat, David, Tsao, Ming-Sound, Wilner, Keith, Buller, Richard, Pitman Lowenthal, Susan, Arifeen, Shams, Binko, Justin, & Alam, Mahmood (2014) National working group meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 10(S2), pp. 11-17.
The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||Special Issue: Molecular Diagnostics in NSCLC Management. Review articles based on Pfizer-sponsored Lung Symposium and working group on ALK diagnostics, held around World Conference on Lung Cancer (WCLC) 2013, Sydney, Australia. Preparing for tomorrow: Molecular diagnostics and the changing NSCLC landscape, 27th October 2013, Sydney, Australia. National Working Group Meeting on ALK diagnostics in lung cancer, 31st October 2013, Sydney Australia. Publication of this supplement has been supported through an independent educational grant from Pfizer Australia|
|Keywords:||ALK testing; fluorescence in situ hybridization; immunohistochemistry; molecular diagnostics; nonsmall cell lung cancer|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200)|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2014 Wiley Publishing Asia Pty Ltd|
|Deposited On:||03 Nov 2014 23:37|
|Last Modified:||17 Jun 2015 03:13|
Repository Staff Only: item control page